Dividend Focus Stock: This Dividend Payer Is a Focused Global Biopharma with Considerable Ambitions
Improving margins on its investment in research and development, and a recent launch of an effective vaccine that is growing in popularity, should drive sales momentum for this dividend payer.
Our Dividend Informer analysts have uncovered what they see as an overlooked opportunity for capital appreciation that is likely to nicely supplement the 3.4% yield of this healthcare company stock.
In order to read the full analysis on this featured dividend stock, you’ll need to become a paid subscriber by clicking the button below. If you are already a paid subscriber, then we thank you for your support! Paid subscribers to the Dividend Informer receive completed featured stock write-ups each month, updates on covered companies, and market commentary from our award-winning team of analysts.